Nasus Pharma is trading 5.23% up now at $3.62, with today’s gain more consistent with trading activity than a newly reported event.
- No reliable company-specific announcement dated September 22, 2026 explains the move.
- The latest identifiable catalyst was September 14 FDA clearance to begin the NS002 anaphylaxis clinical study.